AlphAIalphai — Financial news for AI agents
rttnews.comSEP 42 min read$PDEX

Pro-Dex Jumps On Higher Q4 Earnings And Revenue Growth

Pro-Dex Inc. (PDEX) reported Q4 2026 revenue growth of 17% to $20.41M and net income growth of 140% to $2.86M. Full-year revenue rose 16% to $77.55M, with net income up 52% to $13.66M. Shares surged over 16% following the earnings release.

Original reporting
rttnews.com
Published Sep 4, 2026, 3:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 4, 2026, 4:33 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Pro-Dex Jumps On Higher Q4 Earnings And Revenue Growth — source image
Source · rttnews.com
Decision brief

The 30-second read

$PDEXBullishHigh
01

Why it matters

Earnings beat drives a 16% intraday rally, suggesting short‑term buying interest.

02

Market read

First‑report earnings with strong growth and a notable price move make this a high‑value trading story.

03

What to watch

Potential supply‑chain constraints for battery‑powered instruments.

Relevance 8/10Novelty 8/10Timing: post‑earnings release today

Background

Pro‑Dex Inc. reports its Q4 and FY 2026 financials, highlighting revenue growth and profit expansion.

Company-level read

Ticker impact

$PDEXBullishHigh confidence
Context

Q4 earnings and full-year results posted, revenue up 17% YoY and net income up, driving a 16% share jump.

Expected impact

Potential continued rally toward recent highs if momentum persists.

Evidence & confidence

First‑report earnings with double‑digit revenue growth and a sizable same‑day price jump indicate fresh, actionable information.

Market effects

Sector

Positive signal for medical device and surgical instrument sector.

Regional

U.S. biotech/medical device stocks may see modest lift.

Global

Limited to niche medical device space.

Counterpoint

What could challenge this read

Valuation may already price in growth; watch for margin pressure.

Key entities

  • Company
    Pro‑Dex Inc.

    Developer and manufacturer of powered surgical instruments.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 3
$PDEXMed

PRO DEX INC (PDEX): Results of Operations and Financial Condition

PRO DEX INC (PDEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Contact: Richard L. Van Kirk, Chief Executive Officer (949) 769-3200 For Immediate Release PRO-DEX, INC. ANNOUNCES FISCAL 2026 FOURTH QUARTER AND FULL-YEAR RESULTS IRVINE, CA, September 3, 2026 - PRO-DEX, INC. (NasdaqCM: PDEX) t oday announced financial results for i

SEC EDGAR 8-K2 min
SEP 4
$VIRCMed

VIRCO MFG CORPORATION (VIRC): Results of Operations and Financial Condition

VIRCO MFG CORPORATION (VIRC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Virco Reports Revenue through Six Months Declined 6.1% to $118.2 Million from $125.8 Million, as Rebalancing of School Furniture Market Continues • Operating Income of $10.5 Million for Second Quarter Remains Above Long-Term Average • Shipments Plus Backlog of $162.5

SEC EDGAR 8-K2 min
SEP 4
$LULUMedAI 8/10

Lululemon earnings analysis: questions answered and next catalysts

Lululemon's Q2 earnings beat included a $0.86 per share tariff-refund benefit, while revenue missed estimates and full-year guidance was cut sharply. The stock fell 17.77% to $100.13. Management cited product execution issues and weaker traffic, with women's leggings sales declining 20%. Fiscal 2026 revenue guidance was reduced to $10.35B–$10.50B, and Q3 guidance expects a 10%–11% revenue decline.

investing.com3 min